Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
Amid the weight-loss drug frenzy, the India heads of Eli Lilly and Novo Nordisk — makers of the world’s most coveted obesity drugs — lay out their playbooks ahead of the March expiry of semaglutide’s patent. In exclusive interviews with Rica Bhattacharyya, Eli Lilly’s Winselow Tucker and Novo Nordisk’s Vikrant Shrotriya detail their strategies on…